吉西他滨联合卡铂或顺铂治疗晚期三阴乳腺癌的疗效观察  

Gemcitabine and carboplatin or cisplatin combination for metastatic triple-negative breast cancer

作　　者：杨慧[1] 黄海欣[1] 李桂生[1] 

机构地区：[1]柳州市工人医院肿瘤科,广西柳州545005

出　　处：《现代肿瘤医学》2014年第5期1076-1078,共3页Journal of Modern Oncology

摘　　要：目的:比较吉西他滨联合卡铂(GC)方案与吉西他滨联合顺铂(GP)方案治疗晚期三阴乳腺癌的疗效及毒副反应。方法:将57例蒽环类及紫杉类耐药的晚期三阴乳腺癌患者分为GC组(29例)和GP组(28例),观察两组的疗效及毒副反应。结果:GC组和GP组的有效率分别为62.1%和57.1%(P>0.05);两组的中位肿瘤进展时间(TTP)分别为5.4个月和5.6个月,中位生存期分别为8.3个月和9.0个月,均无显著性差异(P>0.05)。GC组的Ⅲ-Ⅳ度胃肠道反应发生率(6.9%)明显低于GP组(28.6%)(P<0.05),而GC组Ⅲ-Ⅳ度粒细胞减少率(31.0%)较GP组(14.3%)明显升高(P<0.05)。结论:吉西他滨联合卡铂方案二线治疗晚期三阴乳腺癌疗效肯定,较吉西他滨联合顺铂有效率相似,GC方案治疗组Ⅲ/Ⅳ度中性粒细胞减少症发生率高,GP方案治疗组Ⅲ/Ⅳ度胃肠道反应发生率高,在临床使用方面可以根据患者的特点选择具体的治疗方案。Objective：To investigate the resPonse and toxicity of the gemcitabine Plus carboPlatin（GC）and gem-citabine Plus cisPlatin（GP）in Pretreated metastatic triPle - negative breast cancer（TNBC）Patients. Methods：A to-tal of 57 Patients were divided into two grouPs：GC grouP（29 Patients）and GP grouP（28 Patients）. The resPonse,tox-icity were comPared. Results：The resPonse rate（RR）were 62. 1% and 57. 1% in the GC and GP grouP resPectively, there was no significant difference between them（P ﹥ 0. 05）. The median time to Progression（TTP）and median sur-vival time were 5. 4 months,8. 3 months in GC grouP,and 5. 6 months,9. 0 months in GP grouP,there was no signifi-cant difference between them（P ﹥ 0. 05）. Grade Ⅲ - Ⅳ nausea/ vomiting in GC grouP was lower than that in GP grouP（6. 9% vs 28. 6% ,P ﹤ 0. 05）. Grade Ⅲ - Ⅳ leukoPenia in GC grouP was higher than that in GP grouP （31. 0% vs 14. 3% ,P ﹤ 0. 05）. Conclusion：The GC regimen is similar to GP regimen,but grade Ⅲ - Ⅳ leukoPenia in GC grouP was higher than that in GP grouP,grade Ⅲ - Ⅳ nausea/ vomiting in GC grouP was lower than that in GP grouP.

关 键 词：三阴乳腺癌 吉西他滨 卡铂 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]